Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Completed · Phase 1

Conditions studied: Type 2 Diabetes Mellitus

In brief

To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects

Key facts

Study ID

NCT00930865

Run by

AstraZeneca

People needed

42

Starts

2009-07-01

Expected to finish

2009-09-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Body Mass Index (BMI) of 18 to 32 kg/m², inclusive. BMI = weight (kg)/ [height (m)]²
• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized and men, ages 18 to 45

You may not qualify if…

• WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period
• Any significant acute or chronic medical illness
• Current or recent (within 3 months) gastrointestinal disease
• Current smoker or recent (within 1 month) history of regular tobacco use
• Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population
• Abnormal urinalysis at screening
• Glucosuria at screening
• Abnormal liver functions tests (ALT, AST or total bilirubin > 10 % ULN)
• Presence of edema on physical exam
• History of diabetes mellitus
• History of heart failure
• History of renal insufficiency
• History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
• Positive urine screen for drugs of abuse either at screening or before dosing
• Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or HIV-1, -2 antibody
• History of allergy to SGLT2 inhibitors, bumetanide (or related compounds)
• History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
• Prior exposure to dapagliflozin within 3 months of Day -1
• Exposure to any investigational drug or placebo within 4 weeks of Day -1
• Use of any prescription drugs within 4 weeks or over-the-counter acid controllers within 2 weeks prior to study drug administration
• Use of any other drugs, including over-the-counter medications within 1 week and herbal preparations, within 2 weeks prior to study drug administration
• Use of an oral, injectable or implantable hormonal contraceptive agent within 3 months of study drug administration

Where it is running

• Ppd Development, Lp — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.